Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kevin Bitterman Insider Profile
4 Followers
Kevin Bitterman, Director at Genocea Biosciences, holds 1.15M shares in Disc Medicine (Ticker: IRON), holds 2.52M shares in Akero Therapeutics (Ticker: AKRO), holds 4.16M shares in Editas Medicine (Ticker: EDIT). Most recently, Kevin Bitterman Bought ― shares of Disc Medicine on Jun 20, 2024 for an estimated value of 8.00M.
Profitable Transactions
8 out of 17 Profitable Transactions
Average Return
-16.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kevin Bitterman holds in companies
Most Profitable Insider Trade
The most profitable trade made by Kevin Bitterman
Kevin Bitterman's Trading History
Genocea Biosciences
Feb 11, 2014
Director
Uninformative Buy
―
$31.93K
Editas Medicine
May 24, 2017
Director, Ten Percent Owner
Informative Sell
17.00M
$9.85M
Akero Therapeutics
Jun 03, 2021
Director
Uninformative Sell
459.61K
$78.72M
Disc Medicine
Jun 20, 2024
Director
Informative Buy
8.00M
$72.97M
List of latest transactions for each holding click on a transaction to see Kevin Bitterman's performance on stock
You May Also Like
Kevin Bitterman insider profile FAQ
What is the percentage of profitable transactions made by Kevin Bitterman?
The percentage of profitable transactions made by Kevin Bitterman is 47%.
What is the average return per transaction made by Kevin Bitterman?
The average return per transaction made by Kevin Bitterman is -16.50%.
What stocks does Kevin Bitterman hold?
Kevin Bitterman holds: GNCAQ, EDIT, AKRO, IRON stocks.
What was Kevin Bitterman’s latest transaction?
Kevin Bitterman latest transaction was an Informative Buy of $8.00M.
What was Kevin Bitterman's most profitable transaction?
Kevin Bitterman’s most profitable transaction was an Informative Buy of IRON stock on June 20, 2024. The return on the trade was 57.50%.
What is Kevin Bitterman's role in Genocea Biosciences?
Kevin Bitterman's role in Genocea Biosciences is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.